Australia markets open in 47 minutes

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6100+0.0141 (+2.37%)
At close: 04:00PM EST
0.6500 +0.04 (+6.56%)
After hours: 05:11PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.5959
Open0.5890
Bid0.6100 x 3000
Ask0.6293 x 1000
Day's range0.5890 - 0.6483
52-week range0.5560 - 3.3600
Volume253,205
Avg. volume269,480
Market cap48.682M
Beta (5Y monthly)0.40
PE ratio (TTM)N/A
EPS (TTM)-0.3880
Earnings date01 Mar 2022 - 07 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.00
  • Zacks

    Down 13.9% in 4 Weeks, Here's Why Soleno Therapeutics, Inc. (SLNO) Looks Ripe for a Turnaround

    Soleno Therapeutics, Inc. (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

  • GlobeNewswire

    Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare disease, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to a new employee. The independent members of the Board of Directors of Soleno approved the grant of a non-qualified stock option to purchase 75,000 shares of common stock to Michael Woloschak, S

  • GlobeNewswire

    Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

    REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine months ended September 30, 2021. “The recently announced top-line results from Soleno’s ongoing open-label extension study evaluating DCCR for the treatment of Prader-Willi syndrome (PWS), and th